OSLO/ LONDON: 26 AUGUST, 2021: Exact Therapeutics AS ("EXACT-Tx", Euronext
Growth: EXTX), a clinical stage precision medicine company evaluating Acoustic
Cluster Therapy (ACT®) across multiple therapeutic areas, today announces that
its Chief Executive Officer, Dr Rafiq Hasan, will be presenting at the Pareto
Securities 12th Annual Healthcare Conference on Wednesday, 1 September at
12.00pm CET.


For more information, please contact:

Dr Rafiq Hasan
CEO EXACT Therapeutics
Email: Rafiq@exact-tx.com

Optimum Strategic Communications
Mary Clark/ Manel Mateus/ Vici Rabbets
Tel: +44 (0) 208 078 0457
Email: Exact@optimumcomms.com

About EXACT-Tx
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com

About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. 
ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes.